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 “Our greatest glory is not in never falling, but in rising every time we fall.” 
Attributed to Confucius 
 
 
Thousands of papers on hypertrophic cardiomyopathy have been published since Donald 
Teare’s landmark description of the disease in 1958, but in spite of considerable advances 
in its management, clinicians still struggle with the treatment of symptoms in people 
afflicted by the condition. Patients with hypertrophic cardiomyopathy often complain of 
exertional chest pain, dyspnea and fatigue [1]. The underlying mechanisms are complex 
and vary between patients; in some, heart failure symptoms are caused by diastolic 
dysfunction with preserved ejection fraction and in others by systolic left ventricular 
dysfunction or left ventricular outflow tract obstruction (with or without mitral 
insufficiency). Atrial fibrillation is frequent in both scenarios and often exacerbates 
symptoms. 
 
When caused by dynamic left ventricular outflow tract obstruction, exertional symptoms 
can be managed effectively with drugs or interventions such as surgical septal myectomy 
and alcohol septal ablation. However, treatment options in non-obstructive patients are 
usually much less successful and are often associated with side-effects. In this edition of 
the journal, Olivotto and colleagues report a multicenter, double-blind, phase 2 study of 
ranolazine–an inhibitor of the cardiac late sodium current (INaL)–in 80 adult patients with 
non-obstructive hypertrophic cardiomyopathy who were randomly assigned to placebo or 
ranolazine 1000 mg bid for 5 months [2]. INaL is an inward membrane ion current that 
occurs predominantly during phase 2 and early phase 3 of repolarization. In normal 
cardiomyocytes, its contribution to the duration of the action potential is minimal, but in 
diseases states INaL is increased causing intracellular Na
+ overload and a decrease of the 
transmembrane electrical gradient that favors reversal of the Na+/Ca2+ exchanger and 
cytosolic Ca2+ overload [3]. In a recent study of myocardial tissue removed at the time of 
septal myectomy, INaL was found to be ≈2-fold greater in cardiomyocytes from patients 
with hypertrophic cardiomyopathy compared to those taken from control tissue [3]. This 
difference was associated with increased diastolic Nai
+ and Cai
2+concentrations, enhanced 
susceptibility to triggered arrhythmias, hypercontractility, and increased diastolic tension, 
all of which were significantly reduced or abolished by ranolazine.  
 
Based on these preclinical findings, ranolazine might be expected to improve diastolic 
dysfunction and microvascular perfusion and to reduce ventricular arrhythmias in 
hypertrophic cardiomyopathy. Sadly, in this well conducted randomized trial, 
ranolazine showed no effect on exercise performance, plasma pro-brain natriuretic 
peptide levels, diastolic left ventricular function or quality of life. This finding adds to a 
rather depressing lack of efficacy in other studies [4] and the premature termination of 
trials examining a novel late sodium current inhibitor, eleclazine [5], and the drug 
perhexiline [6].  
 
Nevertheless, Olivotto and colleagues are to be congratulated on overcoming the 
considerable challenges involved in conducting a randomized trial in hypertrophic 
cardiomyopathy in the first place. Although not a rare disease by most current 
definitions, hypertrophic cardiomyopathy shares with them a number of features that 
present obstacles to the conduct of randomized trials including a heterogeneous clinical 
phenotype and small patient populations clustered in a few tertiary care centers. The 
randomized controlled trial is the reference standard for establishing clinical efficacy of 
investigational products as it minimizes selection bias, distributes confounders between 
study groups and limits investigator and participant bias in the assessment of outcomes. 
However, this classical approach to clinical trial design is costly, time-consuming, and 
often requires large sample sizes to uncover small therapeutic effects— all of which are 
problematic in uncommon diseases such as hypertrophic cardiomyopathy.  
A second fundamental issue is the selection of end-points. Like many rare disorders, 
hypertrophic cardiomyopathy is a chronic disorder that evolves slowly over decades and 
while it is associated with death from ventricular arrhythmia and heart failure, the 
annual event rates even in tertiary center populations are low. This means that 
conventional hard end-point trials are difficult to design, a fact recognized by licensing 
authorities who increasingly seek validated measures of disease activity or disease 
progression as surrogate markers of efficacy in rare diseases.  
In this study, the primary end-point was a change in peak oxygen consumption. When 
performed by experienced personnel, cardiopulmonary exercise testing with 
simultaneous measurement of respiratory gases is an objective measure of functional 
limitation [7]. Studies in patients with hypertrophic cardiomyopathy have shown that 
cardiopulmonary exercise testing can aid differential diagnosis and predict clinical 
outcomes, in particular heart failure [8]. However, its value as a surrogate end-point for 
response to an intervention requires further study as the complex mechanism of exercise 
limitation in hypertrophic cardiomyopathy is such that it might be possible to reduce 
symptoms–for example by alleviating exercise induced myocardial ischemia or reducing 
elevated filling pressures–without changing left ventricular stroke volume or cardiac 
output, necessary prerequisites for an improvement in peak oxygen consumption. One 
alternative might be to use patient reported symptoms instead but these are often 
dismissed as too subjective for the purposes of trials.  However, this seems somewhat 
paradoxical given that they are regarded as sufficiently robust in real world clinical 
practice to select patients for sometimes risky interventions. 
 
In spite of the many challenges of performing trials in hypertrophic cardiomyopathy, 
there are grounds for optimism about the future. The problem of cohort size is being 
solved by the development of international collaborations that provide the basis for 
larger trials powered to detect reductions in hard end-points [9]. There is also growing 
appreciation of the limitations of treating all patients as if they have the same disease. 
Hypertrophic cardiomyopathy is an umbrella term that encompasses a wide range of 
genetic and non-genetic diseases and as patient cohorts increase in size and genotyping 
becomes mainstream, there is an increasing focus on specific therapeutic targets that 
might form the basis of a more bespoke approach to therapy. The critical message from 
this paper is that we owe it to patients to continue the effort to discover new approaches 
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